574 related articles for article (PubMed ID: 15368653)
1. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
Gross DJ; Schondelmeyer SW; Raetzman SO
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
[TBL] [Abstract][Full Text] [Related]
2. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
3. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
Rosenberg ME; Rosenberg SP
JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
[TBL] [Abstract][Full Text] [Related]
4. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
5. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
Augurzky B; Göhlmann S; Gress S; Wasem J
Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
[TBL] [Abstract][Full Text] [Related]
6. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
[TBL] [Abstract][Full Text] [Related]
7. Rising drug prices drive US manufacturers' revenues, analysis finds.
McCarthy M
BMJ; 2015 Oct; 351():h5376. PubMed ID: 26446098
[No Abstract] [Full Text] [Related]
8. Medicare program; manufacturer submission of manufacturer's average sales price (ASP) data for Medicare Part B drugs and biologicals. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2004 Sep; 69(179):55763-5. PubMed ID: 15372731
[TBL] [Abstract][Full Text] [Related]
9. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Pavenik N
Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
[TBL] [Abstract][Full Text] [Related]
10. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
11. Social Security cost-of-living adjustments and the Consumer Price Index.
Burdick C; Fisher L
Soc Secur Bull; 2007; 67(3):73-88. PubMed ID: 18605219
[TBL] [Abstract][Full Text] [Related]
12. Recent trends in systemic psoriasis treatment costs.
Beyer V; Wolverton SE
Arch Dermatol; 2010 Jan; 146(1):46-54. PubMed ID: 20083692
[TBL] [Abstract][Full Text] [Related]
13. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
[TBL] [Abstract][Full Text] [Related]
14. Determinants of branded prescription medicine prices in OECD countries.
Kanavos PG; Vandoros S
Health Econ Policy Law; 2011 Jul; 6(3):337-67. PubMed ID: 21676345
[TBL] [Abstract][Full Text] [Related]
15. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
16. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
[TBL] [Abstract][Full Text] [Related]
17. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
Openshaw MS
Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
[TBL] [Abstract][Full Text] [Related]
18. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs.
Laing RO; McGoldrick KM
Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S194-207. PubMed ID: 11144553
[TBL] [Abstract][Full Text] [Related]
20. Examining the production costs of antiretroviral drugs.
Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
